Genetic and epigenetic modulation of growth hormone sensitivity studied with the IGF-1 generation test

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 6, 2015, Pages E919-E925

  Meriem, Ouni ^a   Anne Laure, Castell ^a,b   Agnès, Linglart ^a,b   Pierre, Bougnères ^a,b,c  

^a Institut National de la Santé et de la Recherche   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GROWTH HORMONE RECEPTOR; SOMATOMEDIN C; CARRIER PROTEIN; HUMAN GROWTH HORMONE; SOMATOTROPIN-BINDING PROTEIN;

ARTICLE; CHILD; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SHORT STATURE; ADOLESCENT; DRUG RESISTANCE; ENDOCRINE SYSTEM EXAMINATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; GROWTH DISORDERS; METABOLISM; PHYSIOLOGY;

ADOLESCENT; CARRIER PROTEINS; CHILD; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DNA METHYLATION; DRUG RESISTANCE; EPIGENESIS, GENETIC; FEMALE; GENOTYPE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84930794702     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1413     Document Type: Article

References (55)

1. Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2009;19(1):1-11.
2. Dahlgren J, Kriström B, Niklasson A, Nierop AFM, Rosberg S, Albertsson-Wikland K. Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak. 2007;7:40.
3. Lee PA, Sävendahl L, Oliver I, et al. Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int J Pediatr Endocrinol. 2012;2012(1):22.
4. Collett-Solberg PF. Update in growth hormone therapy of children. J Clin Endocrinol Metab. 2011;96(3):573-579.
5. Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93(11):4342-4350.
6. Sotos JF, Tokar NJ. Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit. Int J Pediatr Endocrinol. 2014;2014(1):15.
7. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14(2):143-154.
8. Cohen P, Germak J, Rogol AD, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab. 2010;95(5):2089-2098.
9. Cohen P, Rogol AD, Weng W, et al. Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels. Clin Endocrinol (Oxf). 2013;78(3):405-414.
10. Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480-2486.
11. Rosenfeld RG. The Pharmacogenomics of Human Growth. J Clin Endocrinol Metab. 2006;91(3):795-796.
12. Ranke MB. Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol. 2013;9(6):325-334.
13. Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res. 2005;15(suppl A):S13-S20.
14. Kriström B, Lundberg E, Jonsson B, Albertsson-Wikland K, Study Group. IGF-1 and growth response to adult height in a randomized GH treatment trial in short non-GH-deficient children. J Clin Endocrinol Metab. 2014;99(8):2917-2924.
15. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36(7):720-724.
16. Bougnères P. The exon-3 deletion of the growth hormone receptor (GHR) gene still has a limited impact in clinical endocrinology. J Clin Endocrinol Metab. 2010;95(1):56-59.
17. Renehan AG, Solomon M, Zwahlen M, et al. Growth hormone receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis. Am J Epidemiol. 2012;175(9): 867-875.
18. Wassenaar MJE, Dekkers OM, Pereira AM, et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(10):3721-3730.
19. Rosenfeld RG. Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature. Eur J Endocrinol. 2007;157(suppl 1):S27-S31.
20. Kao PC, Matheny AP, Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab. 1994; 78(2):310-321.
21. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996;98(11):2612-2651.
22. Palles C, Johnson N, Coupland B, et al. Identification of genetic variants that influence circulating IGF-1 levels: a targeted search strategy. Hum Mol Genet. 2008;17(10):1457-1415.
23. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF-1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF-1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 2006; 15(1):1-101.
24. Wong H-L, DeLellis K, Probst-Hensch N, et al. A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev. 2005;14(1):144-151.
25. Ester WA, Hokken-Koelega ACS. Polymorphisms in the IGF-1 and IGF-1R genes and children born small for gestational age: results of large population studies. Best Pract Res Clin Endocrinol Metab. 2008;22(3):415-431.
26. Vaessen N, Janssen JA, Heutink P, et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet. 2002;359(9311):1036-1037.
27. Frayling TM, Hattersley AT, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in UK populations. Diabetes. 2002;51(7):2313-2316.
28. Toyoshima MTK, Castroneves LA, Costalonga EF, Mendonca BB, Arnhold IJP, Jorge AAL. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clin Endocrinol (Oxf). 2007;67(4):500-504.
29. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther. 2012;92(6):727-736.
30. Ouni M, Belot MP, Castell AL, Fradin D, Bougnères P. The IGF-1 P2 promoter is a major epigenetic locus for GH responsiveness. Pharmacogenomics. Published online ahead of print March 13, 2015. doi:10.1038/tpj.2015.26.
31. Coutant R, Dörr H-G, Gleeson H, Argente J. Diagnosis of endocrine disease: limitations of the IGF-1 generation test in children with short stature. Eur J Endocrinol. 2012;166(3):351-373.
32. Cole T j., Ahmed M l., Preece M a., Hindmarsh P, Dunger D b. The relationship between Insulin-like Growth Factor 1, sex steroids and timing of the pubertal growth spurt. Clin Endocrinol (Oxf). Published online ahead of print November 23, 2014. doi: 10.1111/cen.12682.
33. Alberti C, Chevenne D, Mercat I, et al. Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem. 2011;57(10): 1424-1435.
34. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001;86(11):5176-5183.
35. Copeland KC, Underwood LE, Van Wyk JJ. Induction of immunoreactive somatomedin C human serum by growth hormone: doseresponse relationships and effect on chromatographic profiles. J Clin Endocrinol Metab. 1980;50(4):690-697.
36. Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatr. 1995;127(2):244-250.
37. Rudman D, Kutner MH, Blackston RD, Cushman RA, Bain RP, Patterson JH. Children with normal-variant short stature: treatment with human growth hormone for six months. N Engl J Med. 1981; 305(3):123-131.
38. Bernabeu I, Alvarez-Escolá C, Quinteiro C, et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab. 2010;95(1):222-291.
39. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2(9):2265-2275.
40. Schwarze CP, Wollmann HA, Binder G, Ranke MB. Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children. Acta Paediatr Suppl (Oslo Nor). 1999;88(428):200-208.
41. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84(11):3956-3601.
42. Bouhours-Nouet N, Gatelais F, Boux de Casson F, Rouleau S, Coutant R. The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature. J Clin Endocrinol Metab. 2007;92(2):629-635.
43. Clayton PE, Freeth JS, Whatmore AJ, Ayling RM, Norman MR, Silva CM. Signal transduction defects in growth hormone insensitivity. Acta Paediatr Suppl (Oslo Nor). 1999;88(428):174-178; discussion 179.
44. López-Bermejo A, Buckway CK, Rosenfeld RG. Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol Metab TEM. 2000;11(2):39-49.
45. Mill J, Heijmans BT. From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet. 2013;14(8):585-594.
46. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet. 2011;12(8):529-541.
47. Feinberg AP, Irizarry RA, Fradin D, et al. Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med. 2010;2(49):49ra67.
48. Talens RP, Boomsma DI, Tobi EW, et al. Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology. FASEB J. 2010;24(9):3135-3144.
49. Rotwein P, Pollock KM, Didier DK, Krivi GG. Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem. 1986;261(11):4828-4832.
50. Rotwein P. Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors. 1991;5(1):3-181.
51. Hall LJ, Kajimoto Y, Bichell D, et al. Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol. 1992;11(4):301-313.
52. Wang Y, Price SE, Jiang H. Cloning and characterization of the bovine class 1 and class 2 insulin-like growth factor-I mRNAs. Domest Anim Endocrinol. 2003;25(4):315-328.
53. Heim MH. The Jak-Stat pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct. 1999;19(1- 4):75-120.
54. Chia DJ, Young JJ, Mertens AR, Rotwein P. Distinct alterations in chromatin organization of the two IGF-I promoters precede growth hormone-induced activation of IGF-I gene transcription. Mol Endocrinol. 2010;24(4):779-789.
55. Chia DJ, Rotwein P. Defining the epigenetic actions of growth hormone: acute chromatin changes accompany GH-activated gene transcription. Mol Endocrinol. 2010;24(10):2038-2049.